ArcticZymes Technologies ASA (FRA:B4V) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:B4V ArcticZymes Technologies ASA FRA:B4V
80 GF Score
Price €1.75
GF Value €2.23
! 1 Warning Sign
View Full Analysis

What is ArcticZymes Technologies ASA Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:B4V
80GF Score
ArcticZymes Technologies ASA FRA:B4V
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ArcticZymes Technologies ASA (FRA:B4V) Overvalued in 2026?

Based on GuruFocus' analysis, ArcticZymes Technologies ASA stock appears to be undervalued. The current stock price of €1.75 is trading 21.7% below its estimated GF Value™ of €2.23.

Key valuation signals for FRA:B4V:

  • Dividends Received:
  • GF Value™: €2.23 vs. price of €1.75 (21.7% below fair value)
  • GF Score™: 80/100 with 1 warning sign

No single metric tells the full story. See the FRA:B4V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ArcticZymes Technologies ASA Business Description

Address Sykehusveien 23, Tromso, NOR, 9294
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
80GF Score

Get the complete analysis for FRA:B4V

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.75
Price
€2.23
GF Value